GALXC PLUS
Dead / Abandoned — Abandoned — no statement of use filed (as of 10 Oct 2025)
What this means for you
This application is over — abandoned 10 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 90474748
- Mark type
- Design + words
- Filed
- 19 Jan 2021
- Published for opposition
- 16 Jan 2024
- Abandoned
- 10 Oct 2025
- Attorney of record
- Bridget H. Labutta
Goods and services
- Class 005 — Pharmaceuticals: Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNA interference (RNAi) therapy; Oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
- Class 042 — Scientific and technological services: Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections
Owner
- Dicerna Pharmaceuticals, Inc., Lexington, MA, US
- Dicerna Pharmaceuticals, Inc., Lexington, MA, US
Prosecution history
- 10 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 10 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 12 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Sept 2024 — SOU EXTENSION 1 GRANTED
- 12 Sept 2024 — SOU EXTENSION 1 FILED
- 12 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 12 Mar 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Jan 2024 — PUBLISHED FOR OPPOSITION
- 27 Dec 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 13 Dec 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Nov 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Nov 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 10 Nov 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 10 Aug 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED